Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy - PubMed
Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy
Ismail Pasha et al. Pediatr Neurol. 2014 Oct.
Abstract
Background: A unicentre, prospective study was performed to investigate the efficacy of lacosamide as adjunctive therapy in children with refractory partial epilepsy.
Methods: The study was performed at a tertiary care hospital over a period of 30 months between November 2011 and May 2014. Seventy-nine children with refractory partial epilepsy (age 5-15 years) who had failed two or more antiepileptic drugs and in whom lacosamide was used as an add-on drug were enrolled. Lacosamide tablets were administered orally, at a dose of 25 mg for 1 week followed by 50 mg twice daily for the remaining period. Efficacy and tolerability evaluation was performed at every visit of titration, maintenance period (3 months), and two follow-up visits at monthly interval. Electrocardiogram and liver function tests were performed before enrollment and at the end of 3 months of lacosamide therapy. Patient's caregiver or investigator observed adverse events were recorded in a predesigned pro forma.
Results: A total of 79 patients with uncontrolled partial epilepsy screened from 531 epileptic children were enrolled, after they satisfied the inclusion and exclusion criteria. The mean age of children enrolled was 8.8 ± 3.1 years (range 5-15 years); 53 children (67.0%) were boys. Mean weight of the patients was 24.2 ± 9.8 kg. The mean age at the onset of seizures was 6.4 ± 3.5 years. The mean dose of lacosamide administered was 4.1 mg/kg. Three patients (3.8%) dropped out of the study, because of vomiting, aggressive behavior, and poor response, respectively. Of 76 patients (96.2%) entering the maintenance period, 35 patients (44.3%) were seizure free, 32 patients (40.6%) indicated ≥50% reduction in seizure frequency, 3 patients (3.8%) indicated 25-49% seizure reduction, and 9 patients (11.4%) either had no change in seizure frequency or experience increase in seizure frequency.
Conclusion: Lacosamide is an effective add-on antiepileptic drug for children with refractory partial epilepsy and is well tolerated.
Keywords: antiepileptic drug; children; lacosamide; refractory epilepsy; tolerability.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Grosso S, et al. Eur J Paediatr Neurol. 2014 Jan;18(1):55-9. doi: 10.1016/j.ejpn.2013.08.006. Epub 2013 Oct 3. Eur J Paediatr Neurol. 2014. PMID: 24129195
-
Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy.
Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ, Hwang YS, Hwang H. Kim JS, et al. Brain Dev. 2014 Jun;36(6):510-5. doi: 10.1016/j.braindev.2013.07.003. Epub 2013 Aug 12. Brain Dev. 2014. PMID: 23948372
-
Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Husain A, et al. Epilepsia. 2012 Mar;53(3):521-8. doi: 10.1111/j.1528-1167.2012.03407.x. Epilepsia. 2012. PMID: 22372628 Clinical Trial.
-
Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.
Ben-Menachem E. Ben-Menachem E. Drugs Today (Barc). 2008 Jan;44(1):35-40. doi: 10.1358/dot.2008.44.1.1178468. Drugs Today (Barc). 2008. PMID: 18301802 Review.
-
Simoens S. Simoens S. Curr Med Res Opin. 2011 Jul;27(7):1329-38. doi: 10.1185/03007995.2011.582863. Epub 2011 May 12. Curr Med Res Opin. 2011. PMID: 21561394 Review.
Cited by
-
Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy.
Driessen JT, Wammes-van der Heijden EA, Verschuure P, Fasen KCFM, Teunissen MWA, Majoie HJM. Driessen JT, et al. Epilepsy Behav Rep. 2022 Nov 14;21:100574. doi: 10.1016/j.ebr.2022.100574. eCollection 2023. Epilepsy Behav Rep. 2022. PMID: 36545476 Free PMC article.
-
Yildiz EP, Ozkan MU, Bektas G, Uzunhan TA, Aydinli N, Caliskan M, Ozmen M. Yildiz EP, et al. Childs Nerv Syst. 2017 Nov;33(11):2023-2027. doi: 10.1007/s00381-017-3586-8. Epub 2017 Sep 7. Childs Nerv Syst. 2017. PMID: 28884208
-
The therapeutic effects of lacosamide on epilepsy-associated comorbidities.
He Z, Li J. He Z, et al. Front Neurol. 2023 Mar 16;14:1063703. doi: 10.3389/fneur.2023.1063703. eCollection 2023. Front Neurol. 2023. PMID: 37006477 Free PMC article. Review.
-
Mohammadi T, Nasiri J, Ghazavi MR, Yaghini O, Hoseini N. Mohammadi T, et al. J Res Pharm Pract. 2023 Mar 24;11(3):109-115. doi: 10.4103/jrpp.jrpp_86_21. eCollection 2022 Jul-Sep. J Res Pharm Pract. 2023. PMID: 37304225 Free PMC article.
-
Ngampoopun M, Suwanpakdee P, Jaisupa N, Nabangchang C. Ngampoopun M, et al. Neurol Res Int. 2018 Jun 10;2018:8432859. doi: 10.1155/2018/8432859. eCollection 2018. Neurol Res Int. 2018. PMID: 29984000 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources